It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
Sclerotherapy (STS) probably leads to higher adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
Sclerotherapy probably leads to higher adverse events ‐ matting ( compared with placebo (moderate certainty).
Sclerotherapy (STS) probably leads to higher adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).
Sclerotherapy probably leads to higher adverse events ‐ hyperpigmentation ( compared with placebo (moderate certainty).
Laser plus sclerotherapy showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (low certainty).
Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
Laser plus sclerotherapy showed no clear difference in adverse events ‐ Hyperpigmentation ( compared with sclerotherapy (low certainty).
Sclerotherapy plus compression showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy alone (low certainty).
Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).
Sclerotherapy (hypertonic saline) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
Sclerotherapy (chromated glycerin) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (low certainty).
Sclerotherapy plus compression showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy alone (moderate certainty).
Sclerotherapy (hypertonic saline) probably leads to lower adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).
Sclerotherapy (chromated glycerin) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (low certainty).
Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).
Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).